Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

2.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

383
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
383
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

278
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
278
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Teratogenicity01:07

Teratogenicity

4.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.3K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

504
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
504

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Racial Differences in Adverse Pregnancy Outcomes and Incident Hypertension: A Mediation Analysis.

Journal of the American Heart Association·2026
Same author

Antiphospholipid syndrome (APS) is a platelet factor 4 (PF4)-centric immunothrombotic disorder.

Blood·2026
Same author

Large-scale proteomics in early pregnancy and timing of onset of hypertensive disorders of pregnancy.

medRxiv : the preprint server for health sciences·2026
Same author

Subtypes of Hypertension 2 to 7 Years After First Pregnancy.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Subclinical Cardiac Dysfunction in Women With Prior Gestational Diabetes: The Hispanic Community Study/Study of Latinos.

Journal of the American Heart Association·2025
Same author

Association Between COVID-19 During Pregnancy and Preterm Birth by Trimester of Infection: Retrospective Cohort Study Using Large-Scale Social Media Data.

Journal of medical Internet research·2025

Related Experiment Video

Updated: Feb 17, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.6K

Thrombocytopenia in pregnancy.

Douglas B Cines1,2, Lisa D Levine3

  • 1Department of Pathology and Laboratory Medicine.

Hematology. American Society of Hematology. Education Program
|December 10, 2017
PubMed
Summary

Pregnancy-related thrombocytopenia, a low platelet count, can signal underlying disorders and requires careful management to protect both mother and fetus. Recent advances aid in diagnosing and treating conditions like immune thrombocytopenia and thrombotic microangiopathies during pregnancy.

More Related Videos

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.4K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.4K

Related Experiment Videos

Last Updated: Feb 17, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.6K
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

1.4K
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.4K

Area of Science:

  • Obstetrics and Gynecology
  • Hematology
  • Maternal-Fetal Medicine

Background:

  • Thrombocytopenia (low platelet count) affects 5-10% of pregnancies, potentially indicating systemic or gestational disorders.
  • Management decisions for thrombocytopenia during pregnancy must consider potential risks to the fetus.
  • Recent advancements have improved understanding and management of common causes of thrombocytopenia in pregnancy.

Purpose of the Study:

  • To provide an updated approach to diagnosing and managing thrombocytopenia in pregnancy.
  • To highlight recent advances in understanding and treating common causes of thrombocytopenia during gestation.
  • To guide hematology consultants in differential diagnosis and management decisions based on clinical presentation.

Main Methods:

  • Review of recent literature (past 5-10 years) on thrombocytopenia in pregnancy.
  • Emphasis on diagnostic criteria for preeclampsia and thrombotic thrombocytopenic purpura (TTP).
  • Evaluation of current treatment strategies for immune thrombocytopenia (ITP) and atypical hemolytic uremic syndrome (aHUS).

Main Results:

  • New diagnostic criteria for preeclampsia are available.
  • Judicious use of ADAMTS13 measurement aids in TTP diagnosis.
  • Anticomplement therapy shows efficacy and safety in pregnancy for aHUS.
  • Management of ITP involves considering risks of medications like TPO-RAs, rituximab, and mycophenolate.

Conclusions:

  • Thrombocytopenia in pregnancy necessitates a systematic diagnostic approach based on trimester, severity, and clinical findings.
  • Careful consideration of maternal treatments and their fetal risks is crucial.
  • Ongoing research rapidly evolves the management of thrombotic microangiopathies and their implications for future pregnancies.